ANALYSIS OF HOMA-IR, FOLLICLE SIZE, AND ESTRADIOL AFTER COMBINATION THERAPY OF METFORMIN AND CLOMIPHENE CITRATE IN POLYCYSTIC OVARY SYNDROME’S PATIENT

Sylvy Medtasya Dzykryanka, Yulistani Yulistani, Budi Santoso

= http://dx.doi.org/10.20473/fmi.v51i3.2828
Abstract views = 802 times | downloads = 714 times

Abstract


PCOS is an ovarian dysfunction syndrome which characterized by the present of unovulation, hyperandrogenism, and polycystic ovarian morphology. The main cause of PCOS is still unclear, but many studies report that genetic factor have a great role. There are also two big concept in PCOS, hyperandrogenism and insulin resistance. Previous research by Ayaz et al (2013) has shown that metformin was given if there has been a resistance of clomiphene citrate. This study was designed to provide metformin and clomiphene citrate combination from the early administration to determine the effectiveness of the combination therapy. The objective of this study is to analyze HOMA-IR value, follicle size, and estradiol concentration after metformin and clomiphene citrate treatment in PCOS patient. Design of this study was an observational longitudinal prospective method. There was only a group with a total sample size 19 women of productive age (18-40 years) diagnosed with PCOS. The pre and post combination therapy was observed for ten weeks. Metformin 500 mg three times daily for ten weeks and clomiphene citrate 100 mg in 3rd day until 7th day of menstruation for two cycles were given to the subjects. The result showed that HOMA-IR value decrease after 10 weeks in which value before therapy was 4.9 ± 2.4 and after therapy 3.7 ± 2.2 with the achievement 21.1% HOMA-IR under 2.5. Estradiol concentration after therapy also decreased from 64.8 ± 24.7 pg/ml to 37.9 ± 17.9 pg/ml in ten weeks this concentration remained the range of the follicular phase estradiol levels. On the other hand, follicle size increased from 4.7 ± 0.6 mm to 10.7 ± 2.2 mm after combination therapy of metformin and clomiphene citrate with the occurrence of ovulation 31.6% but none of the samples were successfully pregnant. It is concluded that women with PCOS, declined HOMA-IR, estradiol, and increased follicle size was associated with a good response to combination therapy of metformin and clomiphene citrate.

Keywords


polycystic ovary syndrome, metformin, clomiphene citrate, HOMA-IR, follicle size, estradiol, PCOS

Full Text:

PDF

References


Ayaz A, Alwan Y, Farooq MU (2013). Metformin-clomiphene citrate vs. clomiphene citrate alone: Polycystic ovarian syndrome. J Hum Reprod Sci 6, 15-18

Balen A (2004). The pathophysiology of polycystic ovary syndrome: trying to understand PCOS and its endocrinology. Best Pract Res Clin Obstet Gynaecol 18, 685-706

Biljan MM, Mahutte NG, Tulandi T, Tan SL (1999). Prospective randomized double-blind trial of the correlation between time of administration and antiestrogenic effects of clomiphene citrate on reproductive end organs. Fertil Steril 71, 633-638

Dunaif A (1997). Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18, 774-800

Falbo A, Orio F, Venturella R, Rania E, Materazzo C, Tolino A, Zullo F, Palomba S (2009). Does metformin affect ovarian morphology in patients with polycystic ovary syndrome? A retrospective cross-sectional preliminary analysis. J Ovarian Res 2, 5

Harwood K, Vuguin P, DiMartino-Nardi J (2007). Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. Horm Res 68, 209-217

Horng SG, Wang TH, Wang HS (2008). Estradiol-to-testosterone ratio is associated with response to metformin treatment in women with clomiphene citrate-resistant polycystic ovary syndrome (PCOS). Chang Gung Med J 31, 477-483

Kashyap S, Wells GA, Rosenwaks Z (2004). Insulin-sensitizing agents as primary therapy for patients with polycystic ovarian syndrome. Hum Reprod 19, 2474-2483

Legro RS, Barnhart HX, Schlaff WD, Carr BR, Diamond MP, Carson SA, Steinkampf MP, Coutifaris C, McGovern PG, Cataldo NA, Gosman GG, Nestler JE, Giudice LC, Leppert PC, Myers ER; Cooperative Multicenter Reproductive Medicine Network (2007). Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 356, 551-566

Lord JM, Flight IH, Norman RJ (2003). Insulin-sensitising drugs (metformin, troglitazone, rosiglita-zone, pioglitazone, D-chiro-inositol) for polycystic ovary syndrome. Cochrane Database Syst Rev, CD003053

Moll E, Bossuyt PM, Korevaar JC, Lambalk CB, van der Veen F (2006). Effect of clomifene citrate plus metformin and clomifene citrate plus placebo on induction of ovulation in women with newly diagnosed polycystic ovary syndrome: randomised double blind clinical trial. BMJ 332, 1485

Norman RJ, Wu R, Stankiewicz MT (2004). Polycystic ovary syndrome. MJA Pract Essen Endocrinol 180, 132-137

Palomba S, Russo T, Orio F Jr, Falbo A, Manguso F, Sammartino A, Tolino A, Colao A, Carmina E, Zullo F (2006). Uterine effects of clomiphene citrate in women with polycystic ovary syndrome: a prospective controlled study. Hum Reprod 21, 2823-2829

Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group (2004). Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19, 41-47

Yen SSC (1986). The human menstrual cycle. In: Yen SSC and Jaffee RB (eds). Reproductive Endocrin-ology: Physiology, Pathophysiology and Clinical Management. Philadelphia, Saunders (WB) Co Ltd, p 200–236


Refbacks

  • There are currently no refbacks.


Copyright (c) 2016 Sylvy Medtasya Dzykryanka, Yulistani Yulistani, Budi Santoso

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Indexed By

View My Stats

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.